A detailed history of Dimensional Fund Advisors LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 47,152 shares of VKTX stock, worth $2.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,152
Previous 62,133 24.11%
Holding current value
$2.5 Million
Previous $1.16 Million 234.43%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$17.4 - $94.5 $260,669 - $1.42 Million
-14,981 Reduced 24.11%
47,152 $3.87 Million
Q4 2023

Feb 07, 2024

SELL
$9.24 - $19.64 $3.37 Million - $7.16 Million
-364,631 Reduced 85.44%
62,133 $1.16 Million
Q3 2023

Nov 09, 2023

SELL
$10.92 - $16.0 $1.17 Million - $1.72 Million
-107,568 Reduced 20.13%
426,764 $4.72 Million
Q1 2023

May 12, 2023

SELL
$8.08 - $17.33 $2.54 Million - $5.45 Million
-314,395 Reduced 37.04%
534,332 $8.9 Million
Q4 2022

Feb 09, 2023

SELL
$2.72 - $9.4 $177,441 - $613,218
-65,236 Reduced 7.14%
848,727 $7.98 Million
Q3 2022

Nov 10, 2022

SELL
$2.55 - $3.89 $943,403 - $1.44 Million
-369,962 Reduced 28.81%
913,963 $2.49 Million
Q2 2022

Aug 12, 2022

SELL
$2.11 - $3.15 $193,191 - $288,414
-91,560 Reduced 6.66%
1,283,925 $3.71 Million
Q1 2022

May 13, 2022

BUY
$3.0 - $4.88 $937,131 - $1.52 Million
312,377 Added 29.38%
1,375,485 $4.13 Million
Q4 2021

Feb 09, 2022

BUY
$4.6 - $6.72 $1.36 Million - $1.99 Million
296,385 Added 38.66%
1,063,108 $4.89 Million
Q3 2021

Nov 12, 2021

BUY
$5.58 - $7.04 $2.4 Million - $3.03 Million
430,845 Added 128.27%
766,723 $4.82 Million
Q2 2021

Aug 12, 2021

BUY
$5.19 - $6.73 $121,830 - $157,980
23,474 Added 7.51%
335,878 $2.01 Million
Q1 2021

May 14, 2021

BUY
$5.74 - $9.67 $654,618 - $1.1 Million
114,045 Added 57.49%
312,404 $1.98 Million
Q4 2020

Feb 25, 2021

BUY
$5.3 - $6.71 $1.05 Million - $1.33 Million
198,359 New
198,359 $1.12 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.07B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.